Molecular patterns in human ulcerative colitis and correlation with response to infliximab

Inflammatory Bowel Diseases

Volumn 20, Issue 12, 2014, Pages 2353-2363

  Halloran, Brendan ^a   Chang, Jessica ^c   Shih, David Q ^b   McGovern, Dermot ^b   Famulski, Konrad ^c,d   Evaschesen, Chad ^a   Fedorak, Richard N ^a   Thiesen, Aducio ^d   Targan, Stephan ^b   Halloran, Philip F ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Dedifferentiation; Infliximab; Microarrays; T cell mediated rejection; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIBIOTIC AGENT; INFLIXIMAB; MESSENGER RNA; STEROID; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; COLON BIOPSY; COLON CROHN DISEASE; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HISTOLOGY; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; ULCERATIVE COLITIS; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; COLITIS, ULCERATIVE; COMPLICATION; DNA MICROARRAY; DRUG EFFECTS; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; GRAFT REJECTION; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOMARKERS; CHILD; COHORT STUDIES; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; GENE EXPRESSION PROFILING; GRAFT REJECTION; HUMANS; IMMUNOENZYME TECHNIQUES; INFLIXIMAB; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84925727319     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000239     Document Type: Article

References (34)

1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
2. Jarcho JA, Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369:754-762.
3. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology. 2005;128:1805-1811.
4. van der Valk ME, Mangen MJJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF therapy: results from the COIN study. Gut. 2013;63:72-79.
5. Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess. 2011;15:1-244.
6. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201.
7. Danese S, Colombel JF, Peyrin-Biroulet L, et al. Review article: the role of anti-TNF in the management of ulcerative colitis-past, present and future. Aliment Pharmacol Ther. 2013;37:855-866.
8. Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010;16:2090-2098.
9. Arijs I, De Hertogh G, Lemaire K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One. 2009;4:e7984.
10. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612-1619.
11. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490-1497.
12. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the Key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-564. Available at: http://www.sciencedirect.com/science/article/pii/S0016508505008723.
13. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-1270.
14. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.
15. Mengel M, Sis B, Kim D, et al. The molecular phenotype of heart transplant biopsies: relationship to histopathological and clinical variables. Am J Transplant. 2010;10:2105-2115.
16. Halloran PF, De Freitas DG, Einecke G, et al. The molecular phenotype of kidney transplants. Am J Transplant. 2010;10:2215-2222.
17. Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transpl. 2007;7:2712-2722.
18. Mengel M, Chang J, Kayser D, et al. The molecular phenotype of 6-Week protocol biopsies from human renal allografts: reflections of prior injury but not future course. Am J Transplant. 2010;11:708-718.
19. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666.
20. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898.
21. Einecke G, Reeve J, Sis B, et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest. 2010;120: 1862-1872.
22. Hidalgo LG, Einecke G, Allanach K, et al. The transcriptome of human cytotoxic T cells: measuring the burden of CTL-associated transcripts in human kidney transplants. Am J Transplant. 2008;8:637-646.
23. Famulski KS, Einecke G, Reeve J, et al. Changes in the transcriptome in allograft rejection: IFN-gamma-induced transcripts in mouse kidney allografts. Am J Transplant. 2006;6:1342-1354.
24. Famulski KS, Einecke G, Sis B, et al. Defining the canonical form of T-cell-mediated rejection in human kidney transplants. Am J Transplant. 2010;10:810-820.
25. Famulski KS, Sis B, Billesberger L, et al. Interferon-g and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm. Am J Transplant. 2008;8:547-556.
26. Famulski KS, De Freitas DG, Kreepala C, et al. Molecular phenotypes of acute kidney injury in kidney transplants. J Am Soc Nephrol. 2012;23: 948-958.
27. Einecke G, Broderick G, Sis B, et al. Early loss of renal transcripts in kidney allografts: relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant. 2007;7:1121-1130.
28. Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cellmediated rejection in human kidney transplant biopsies. Am J Transplant. 2013;13:645-655.
29. Feagins LA, Melton SD, Iqbal R, et al. Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013;19:1477-1482.
30. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2012;120:13-20.
31. Ardizzone S, Cassinotti A, Duca P, et al. Alimentary tract. Clin Gastroenterol Hepatol. 2011;9:483-489.e3.
32. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2568-2576.
33. de Bruyn M, Machiels K, Vandooren J, et al. Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;20:339-352.
34. Bouguen G, Levesque BG, Pola S, et al. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014;20:231-239.